Zentalis presents ASCO data: azenosertib+chemo response linked to Cyclin E1

Zentalis Pharmaceuticals, Inc.

Azenosertib + chemo (paclitaxel, carboplatin, gemcitabine, PLD) shows ORR of 34% across 94 evaluable patients.
Cyclin E1 IHC+ patients had median PFS 9.86 mo vs 3.25 mo for low (HR 0.37, p=0.0078).
RP2D set: azenosertib 300 mg QD 5:2 + paclitaxel 80 mg/m2; RP2D with carboplatin 200 mg QD 5:2.
Phase 3 design proposed comparing azenosertib+chemo vs carboplatin doublet in Cyclin E1+ platinum-sensitive ovarian cancer.
ZN-d5 (BCL-2) + azenosertib phase 1/2 in AML enrolling; no efficacy data yet.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.